Skip to main content

Advertisement

Log in

Involvement of Hepatic Stimulator Substance in Experimentally Induced Fibrosis and Cirrhosis in the Rat

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Liver fibrosis results from sustained wound healing response to chronic liver injury. Liver cirrhosis, the end stage of the fibrotic process, is characterized by disruption of the entire liver architecture and reduced hepatocyte regenerative ability. Hepatic stimulator substance (HSS) is a liver-specific growth factor triggering hepatocyte proliferation in vitro and in vivo. Previous studies have indicated the involvement of HSS in animal models of acute liver injury. The aim of the present study was to investigate the involvement of HSS in the process of fibrosis and cirrhosis induction. Liver fibrosis and cirrhosis were induced in rats by thioacetamide (TAA) administration (300 mg/l) in the drinking water for 3 months, and animals were killed at 0, 1, 2, and 3 months of treatment. TAA administration resulted in progressively increasing liver fibrosis, leading to the onset of cirrhosis at the end of the experimental time. HSS was continuously produced during the course of fibrosis and cirrhosis induction, peaking at the 2nd month of TAA treatment, coinciding with markers of hepatic proliferative capacity, as thymidine kinase activity and DNA biosynthesis. Significantly reduced HSS activity was noted in cirrhotic liver (3rd month). In this case, the exogenous HSS administration during the 3rd month of TAA treatment suppressed the onset of liver cirrhosis, stimulating the hepatic regenerative capacity. Our data indicate the active participation of HSS in the process of fibrosis and cirrhosis induction post-TAA treatment in rats, suggesting also the beneficial effect of HSS treatment against cirrhosis induction with future possible clinical implications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Michalopoulos GK, De Frances MC. Liver regeneration. Science. 1997;276:60–66. doi:10.1126/science.276.5309.60.

    Article  PubMed  CAS  Google Scholar 

  2. Bedossa P, Paradis V. Liver extracellular matrix in health and disease. J Pathol. 2003;200:504–515. doi:10.1002/path.1397.

    Article  PubMed  Google Scholar 

  3. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–218.

    PubMed  CAS  Google Scholar 

  4. Tangkijvanich P, Yee HF Jr. Cirrhosis–can we reverse hepatic fibrosis? Eur J Surg Suppl. 2002;587:100–112.

    PubMed  Google Scholar 

  5. La Brecque DR, Pesch LA. Preparation and partial characterization of hepatic regenerative stimulator substance (SS) from rat liver. J Physiol. 1975;248:273–284.

    Google Scholar 

  6. La Brecque DR. Hepatic stimulator substance. Discovery, characteristics and mechanism of action. Dig Dis Sci. 1991;36:669–673. doi:10.1007/BF01297036.

    Article  Google Scholar 

  7. Francavilla A, DiLeo A, Polimeno L, et al. The effect of hepatic stimulatory substance, isolated from regenerating hepatic cytosol, and 50, 000 and 300, 000 subfractions in enhancing survival in experimental acute hepatic failure in rats treated with d-galactosamine. Hepatology. 1986;6:1346–1351. doi:10.1002/hep.1840060621.

    Article  PubMed  CAS  Google Scholar 

  8. Yao ZQ, Yang WS, Zhang WB, Chen Y, Zhou YX. Hepatic stimulator substance from human fetal liver for treatment of experimental hepatic failure. Chin Med J (Engl). 1992;105:676–683.

    CAS  Google Scholar 

  9. Yao ZQ, Yang WS, Zhang WB, Chen YN, Yang FY. Human hepatic regenerative stimulator substance: partial purification and biological characterization of hepatic stimulator substance from human fetal liver cells. Hepatology. 1990;12:1144–1151. doi:10.1002/hep.1840120512.

    Article  PubMed  CAS  Google Scholar 

  10. Margeli A, Theocharis S, Spiliopoulou C, Horti M, Koutselinis A. Hepatic stimulator substance administration affects cadmium-induced hepatotoxicity in the rat. Int Hepatol Commun. 1996;5:128–134. doi:10.1016/0928-4346(96)00290-3.

    Article  Google Scholar 

  11. Theocharis SE, Margeli AP, Spiliopoulou C, Skaltsas S, Kittas C, Koutselinis A. Hepatic stimulator substance administration enhances regenerative capacity of hepatocytes in cadmium-pretreated partially hepatectomized rats. Dig Dis Sci. 1996;41:1475–1480. doi:10.1007/BF02088575.

    Article  PubMed  CAS  Google Scholar 

  12. Tzirogiannis KN, Panoutsopoulos GI, Demonakou MD, Hereti RI, Alexandropoulou KN, Mykoniatis MG. Effect of hepatic stimulator substance (HSS) on cadmium-induced acute hepatotoxicity in the rat liver. Dig Dis Sci. 2004;49:1019–1028. doi:10.1023/B:DDAS.0000034566.43582.53.

    Article  PubMed  CAS  Google Scholar 

  13. Tzirogiannis KN, Papadimas GK, Kourentzi KT, et al. The role of hepatic stimulator substance (HSS) on liver regeneration arrest induced by cadmium. In Vivo. 2005;19:695–704.

    PubMed  CAS  Google Scholar 

  14. Fan QL, Huang CG, Jin Y, et al. Effects of shark hepatic stimulator substance on the function and antioxidant capacity of liver mitochondria in an animal model of acute liver injury. Acta Biochim Biophys Sin. 2005;37:507–514. doi:10.1111/j.1745-7270.2005.00081.x.

    Article  PubMed  Google Scholar 

  15. Margeli AP, Skaltsas SD, Spiliopoulou CA, Mykoniatis MG, Theocharis SE. Hepatic stimulator substance activity in the liver of thioacetamide-intoxicated rats. Liver. 1999;19:519–525. doi:10.1111/j.1478-3231.1999.tb00085.x.

    Article  PubMed  CAS  Google Scholar 

  16. Theocharis SE, Margeli AP, Agapitos EV, Mykoniatis MG, Kittas CN, Davaris PS. Effect of hepatic stimulator substance administration on tissue regeneration due to thioacetamide-induced liver injury in rats. Scand J Gastroenterol. 1998;33:656–663. doi:10.1080/00365529850171954.

    Article  PubMed  CAS  Google Scholar 

  17. Margeli AP, Manolis E, Skaltsas SN, Tsarpalis KS, Mykoniatis MG, Theocharis SE. Hepatic stimulator substance activity in animal model of fulminant hepatic failure and encephalopathy. Dig Dis Sci. 2002;47:2170–2178. doi:10.1023/A:1020166706833.

    Article  PubMed  CAS  Google Scholar 

  18. Margeli AP, Papadimitriou L, Ninos S, Manolis E, Mykoniatis MG, Theocharis SE. Hepatic stimulator substance administration ameliorates liver regeneration in an animal model of fulminant hepatic failure and encephalopathy. Liver Int. 2003;23:171–178. doi:10.1034/j.1600-0676.2003.00828.x.

    Article  PubMed  CAS  Google Scholar 

  19. Mei MH, An W, Zhang BH, Shao Q, Gong DZ. Hepatic stimulator substance protects against acute liver failure induced by carbon tetrachloride poisoning in mice. Hepatology. 1993;17:638–644. doi:10.1002/hep.1840170418.

    Article  PubMed  CAS  Google Scholar 

  20. Liakos AA, Mykoniatis MG, Kokala ME, Papadimitriou DG, Liatsos GD. Levels of hepatic stimulator substance in liver regenerating process of partially hepatectomized rats pretreated with a single dose of carbon tetrachloride. Dig Dis Sci. 1999;44:1046–1053. doi:10.1023/A:1026685319823.

    Article  PubMed  CAS  Google Scholar 

  21. Zhang BH, Gong DZ, Mei MH. Protection of regenerating liver after partial hepatectomy from carbon tetrachloride hepatotoxicity in rats: role of hepatic stimulator substance. J Gastroenterol Hepatol. 1999;14:1010–1017. doi:10.1046/j.1440-1746.1999.01992.x.

    Article  PubMed  CAS  Google Scholar 

  22. Liatsos GD, Mykoniatis MG, Margeli A, Liakos AA, Theocharis SE. Effect of acute ethanol exposure on hepatic stimulator substance (HSS) levels during liver regeneration: protective function of HSS. Dig Dis Sci. 2003;48:1929–1938. doi:10.1023/A:1026157901805.

    Article  PubMed  CAS  Google Scholar 

  23. Kondili VG, Tzirogiannis KN, Androutsos CD, et al. The hepatoprotective effect of hepatic stimulator substance (HSS) against liver regeneration arrest induced by acute ethanol intoxication. Dig Dis Sci. 2005;50:297–307. doi:10.1007/s10620-005-1598-9.

    Article  PubMed  CAS  Google Scholar 

  24. Hwang TL, Yu HC, Chen PC, Chen MF. Liver regeneration following partial hepatectomy and stimulation by hepatic stimulatory substance in cirrhotic and non-cirrhotic rats. Res Exp Med (Berl). 1995;195:201–208. doi:10.1007/BF02576789.

    Article  CAS  Google Scholar 

  25. Zhang M, Song G, Minuk GY. Effects of hepatic stimulator substance, herbal medicine, selenium/vitamin E, and ciprofloxacin on cirrhosis in the rat. Gastroenterology. 1996;110:1150–1155. doi:10.1053/gast.1996.v110.pm8613004.

    Article  PubMed  CAS  Google Scholar 

  26. Noda S, Masumi S, Moriyama M, et al. Population of hepatic macrophages and response of perfused liver to platelet-activating factor during production of thioacetamide-induced cirrhosis in rats. Hepatology. 1996;24:412–418. doi:10.1002/hep.510240220.

    Article  PubMed  CAS  Google Scholar 

  27. Constantinou MA, Theocharis SE, Mikros E. Application of metabonomics on an experimental model of fibrosis and cirrhosis induced by thioacetamide in rats. Toxicol Appl Pharmacol. 2007;218:11–19. doi:10.1016/j.taap.2006.10.007.

    Article  PubMed  CAS  Google Scholar 

  28. Munro HN, Fleck A. Recent developments in the measurement of nucleic acids in biological materials. A supplementary review. Analyst (Lond). 1966;91:78–88. doi:10.1039/an9669100078.

    Article  CAS  Google Scholar 

  29. Richards GM. Modifications of the diphenylamine reaction giving increased sensitivity and simplicity in the estimation of DNA. Anal Biochem. 1974;57:369–376. doi:10.1016/0003-2697(74)90091-8.

    Article  PubMed  CAS  Google Scholar 

  30. Kahn D, Svanas GW, Eagon PK, et al. Effect of an antiandrogenic H2 receptor antagonist on hepatic regeneration in rats. J Lab Clin Med. 1988;112:232–239.

    PubMed  CAS  Google Scholar 

  31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265–275.

    PubMed  CAS  Google Scholar 

  32. La Brecque DR, Bachur NR. Hepatic stimulator substance: physicochemical characteristics and specificity. Am J Physiol. 1982;242:G281–G288.

    Google Scholar 

  33. Müller A, Machnik F, Zimmermann T, Schubert H. Thioacetamide-induced cirrhosis-like liver lesions in rats–usefulness and reliability of this animal model. Exp Pathol. 1988;34:229–236.

    PubMed  Google Scholar 

  34. Tsukamoto H, Matsuoka M, French SW. Experimental models of hepatic fibrosis: a review. Semin Liver Dis. 1990;10:56–65.

    Article  PubMed  CAS  Google Scholar 

  35. Kuriyama S, Yokoyama F, Inoue H, et al. Sequential assessment of the intrahepatic expression of epidermal growth factor and transforming growth factor-beta1 in hepatofibrogenesis of a rat cirrhosis model. Int J Mol Med. 2007;19:317–324.

    PubMed  CAS  Google Scholar 

  36. Inoue H, Yokoyama F, Kita Y, et al. Relationship between the proliferative capability of hepatocytes and the intrahepatic expression of hepatocyte growth factor and c-Met in the course of cirrhosis development in rats. Int J Mol Med. 2006;17:857–864.

    PubMed  CAS  Google Scholar 

  37. MacIntosh E, Gauthier T, Pettigrew N, Minuk G. Liver regeneration and the effect of exogenous putrescine on regenerative activity after partial hepatectomy in cirrhotic rats. Hepatology. 1992;16:1428–1433. doi:10.1002/hep.1840160620.

    Article  PubMed  CAS  Google Scholar 

  38. Delhaye M, Louis H, Degraef C, et al. Relationship between hepatocyte proliferative activity and liver functional reserve in human cirrhosis. Hepatology. 1996;23:1003–1011. doi:10.1002/hep.510230510.

    Article  PubMed  CAS  Google Scholar 

  39. Delhaye M, Louis H, Degraef C, et al. Hepatocyte proliferative activity in human liver cirrhosis. J Hepatol. 1999;30:461–471. doi:10.1016/S0168-8278(99)80106-8.

    Article  PubMed  CAS  Google Scholar 

  40. Fleig WE, Lehmann H, Wagner H, Hoss G, Ditschuneit H. Hepatic regenerative stimulator substance in the rabbit. Relation to liver regeneration after partial hepatectomy. J Hepatol. 1986;3:19–26. doi:10.1016/S0168-8278(86)80141-6.

    Article  PubMed  CAS  Google Scholar 

  41. Xia JL, Dai C, Michalopoulos GK, Liu Y. Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am J Pathol. 2006;168:1500–1512. doi:10.2353/ajpath.2006.050747.

    Article  PubMed  CAS  Google Scholar 

  42. Kusumoto K, Ido A, Moriuchi A, et al. Repeated intravenous injection of recombinant human hepatocyte growth factor ameliorates liver cirrhosis but causes albuminuria in rats. Int J Mol Med. 2006;17:503–509.

    PubMed  CAS  Google Scholar 

  43. Lin Y, Xie WF, Chen YX, et al. Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes. Liver Int. 2005;25:796–807. doi:10.1111/j.1478-3231.2005.01098.x.

    Article  PubMed  CAS  Google Scholar 

  44. Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med. 1999;5:226–230. doi:10.1038/5593.

    Article  PubMed  CAS  Google Scholar 

  45. Matsuda Y, Matsumoto K, Yamada A, et al. Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/cirrhosis. Hepatology. 1997;26:81–89. doi:10.1002/hep.510260111.

    Article  PubMed  CAS  Google Scholar 

  46. Matsuda Y, Matsumoto K, Ichida T, Nakamura T. Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal hepatic dysfunction in rats. J Biochem. 1995;118:643–649.

    PubMed  CAS  Google Scholar 

  47. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol. 2005;45:605–628. doi:10.1146/annurev.pharmtox.45.120403.095906.

    Article  PubMed  CAS  Google Scholar 

  48. Jiang B, Sawa M, Yamamoto T, Kasai S. Enhancement of proliferation of intrasplenically transplanted hepatocytes in cirrhotic rats by hepatic stimulatory substance. Transplantation. 1997;63:131–135. doi:10.1097/00007890-199701150-00024.

    Article  PubMed  CAS  Google Scholar 

  49. An W, Liu XJ, Lei TG, Dai J, Du GG. Growth induction of hepatic stimulator substance in hepatocytes through its regulation on EGF receptors. Cell Res. 1999;9:37–49. doi:10.1038/sj.cr.7290004.

    Article  PubMed  CAS  Google Scholar 

  50. Gatzidou E, Kouraklis G, Theocharis S. Insights on augmenter of liver regeneration cloning and function. World J Gastroenterol. 2006;12:4951–4958.

    PubMed  CAS  Google Scholar 

  51. Tanigawa K, Sakaida I, Masuhara M, Hagiya M, Okita K. Augmenter of liver regeneration (ALR) may promote liver regeneration by reducing natural killer (NK) cell activity in human liver diseases. J Gastroenterol. 2000;35:112–119. doi:10.1007/s005350050023.

    Article  PubMed  CAS  Google Scholar 

  52. Thasler WE, Schlott T, Thelen P, et al. Expression of augmenter of liver regeneration (ALR) in human liver cirrhosis and carcinoma. Histopathology. 2005;47:57–66. doi:10.1111/j.1365-2559.2005.02172.x.

    Article  PubMed  CAS  Google Scholar 

  53. Li Q, Liu DW, Zhang LM, Zhu B, He YT, Xiao YH. Effects of augmentation of liver regeneration recombinant plasmid on rat hepatic fibrosis. World J Gastroenterol. 2005;11:2438–2443.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stamatios E. Theocharis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gribilas, G., Zarros, A., Zira, A. et al. Involvement of Hepatic Stimulator Substance in Experimentally Induced Fibrosis and Cirrhosis in the Rat. Dig Dis Sci 54, 2367–2376 (2009). https://doi.org/10.1007/s10620-008-0623-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-008-0623-1

Keywords

Navigation